BrainStorm Cell Therapeutics is in the process of conducting a Phase I/II clinical trial to collect preliminary efficacy data as well as test the tolerability and safety of their NurOwn technology for the treatment of ALS. BrainStorm had originally scheduled an international conference call on Tuesday, December 11 to provide updates about this ongoing clinical trial as well as provide information about upcoming clinical trials. However, they deferred this conference call because Brainstorm was selected to present their latest data from their Phase I/II study at the opening presentation of the Israel Neurological Association’s Annual Meeting on December 12, 2012 in Jerusalem, Israel. Dr. Dimitrios Karussis, principal investigator of the study, presented the data from the first 12 patients that have been treated in the trial. BrainStorm plans to reschedule their conference call, so stay tuned to the Weekly Digest for updates!
Click here to read more.Share this: